Home/Filings/4/0001819790-24-000045
4//SEC Filing

Azamian Bobak R. 4

Accession 0001819790-24-000045

CIK 0001819790other

Filed

Mar 18, 8:00 PM ET

Accepted

Mar 19, 7:05 PM ET

Size

12.2 KB

Accession

0001819790-24-000045

Insider Transaction Report

Form 4
Period: 2024-03-15
Azamian Bobak R.
DirectorPresident/CEO and Board Chair
Transactions
  • Exercise/Conversion

    Common Stock

    2024-03-15+28,27436,871 total
  • Sale

    Common Stock

    2024-03-18$30.60/sh10,415$318,69926,456 total
  • Exercise/Conversion

    Restricted Stock Units

    2024-03-1511,29922,599 total
    Common Stock (11,299 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2024-03-1516,97550,925 total
    Common Stock (16,975 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    830,106
Footnotes (6)
  • [F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
  • [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  • [F3]The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
  • [F4]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
  • [F5]RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2023, March 15, 2024, March 15, 2025 and March 15, 2026, subject to the Reporting Person's continuous service.
  • [F6]RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2024, March 15, 2025, March 15, 2026 and March 15, 2027, subject to the Reporting Person's continuous service.

Issuer

Tarsus Pharmaceuticals, Inc.

CIK 0001819790

Entity typeother

Related Parties

1
  • filerCIK 0001827672

Filing Metadata

Form type
4
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 7:05 PM ET
Size
12.2 KB